AB Fundamental Analysis - AB SCIENCE SA

Fundamental Rating

Overall AB gets a fundamental rating of 1 out of 10. We evaluated AB against 54 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of AB have multiple concerns. AB is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year AB has reported negative net income.

AB had a negative operating cash flow in the past year.

AB had negative earnings in each of the past 5 years.

In the past 5 years AB reported 4 times negative operating cash flow.

1.2 Ratios

AB's Return On Assets of -40.25% is on the low side compared to the rest of the industry. AB is outperformed by 79.63% of its industry peers.

		Industry Rank	Sector Rank
ROA	-40.25%
ROE	N/A
ROIC	N/A

ROA(3y)-45.97%

ROA(5y)-51.31%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of AB (90.75%) is better than 92.59% of its industry peers.

In the last couple of years the Gross Margin of AB has grown nicely.

AB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	90.75%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y7.74%

GM growth 5Y5.64%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

AB does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for AB has been increased compared to 1 year ago.

AB has more shares outstanding than it did 5 years ago.

The debt/assets ratio for AB is higher compared to a year ago.

2.2 Solvency

AB has an Altman-Z score of -19.99. This is a bad value and indicates that AB is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -19.99, AB is doing worse than 85.19% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-19.99

ROIC/WACCN/A

WACC7.32%

2.3 Liquidity

AB has a Current Ratio of 0.67. This is a bad value and indicates that AB is not financially healthy enough and could expect problems in meeting its short term obligations.

Looking at the Current ratio, with a value of 0.67, AB is doing worse than 87.04% of the companies in the same industry.

A Quick Ratio of 0.67 indicates that AB may have some problems paying its short term obligations.

AB has a Quick ratio of 0.67. This is amonst the worse of the industry: AB underperforms 83.33% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.67
Quick Ratio	0.67

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

AB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -22.84%.

The Revenue has decreased by -5.08% in the past year.

AB shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.36% yearly.

EPS 1Y (TTM)-22.84%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%1.33%

Revenue 1Y (TTM)-5.08%

Revenue growth 3Y-12.62%

Revenue growth 5Y-7.36%

Sales Q2Q%-8.04%

3.2 Future

Based on estimates for the next years, AB will show a very strong growth in Earnings Per Share. The EPS will grow by 30.66% on average per year.

AB is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -4.65% yearly.

EPS Next Y68.29%

EPS Next 2Y30.66%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year-9.09%

Revenue Next 2Y-4.65%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

AB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AB. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

AB's earnings are expected to grow with 30.66% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y30.66%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

AB does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

AB SCIENCE SA

EPA:AB (12/11/2025, 7:00:00 PM)

1.226

+0.04 (+3.03%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)09-30 2025-09-30

Earnings (Next)05-11 2026-05-11

Inst Owners0.12%

Inst Owner ChangeN/A

Ins Owners30.8%

Ins Owner ChangeN/A

Market Cap81.14M

Revenue(TTM)1.03M

Net Income(TTM)-8.54M

Analysts86

Price Target4.31 (251.55%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)22.25%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)65.79%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)-18.06%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	79
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-0.15

EYN/A

EPS(NY)-0.12

Fwd EYN/A

FCF(TTM)-0.11

FCFYN/A

OCF(TTM)-0.1

OCFYN/A

SpS0.02

BVpS-0.41

TBVpS-0.43

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-40.25%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	90.75%
FCFM	N/A

ROA(3y)-45.97%

ROA(5y)-51.31%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y7.74%

GM growth 5Y5.64%

F-Score3

Asset Turnover0.05

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	27.43%
Cap/Sales	19.77%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.67
Quick Ratio	0.67
Altman-Z	-19.99

F-Score3

WACC7.32%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)39.08%

Cap/Sales(5y)35.14%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-22.84%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%1.33%

EPS Next Y68.29%

EPS Next 2Y30.66%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-5.08%

Revenue growth 3Y-12.62%

Revenue growth 5Y-7.36%

Sales Q2Q%-8.04%

Revenue Next Year-9.09%

Revenue Next 2Y-4.65%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y35.93%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-0.23%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y61.09%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y61.21%

OCF growth 3YN/A

OCF growth 5YN/A

AB SCIENCE SA / AB.PA FAQ

What is the fundamental rating for AB stock?

ChartMill assigns a fundamental rating of 1 / 10 to AB.PA.

What is the valuation status of AB SCIENCE SA (AB.PA) stock?

ChartMill assigns a valuation rating of 1 / 10 to AB SCIENCE SA (AB.PA). This can be considered as Overvalued.

How profitable is AB SCIENCE SA (AB.PA) stock?

AB SCIENCE SA (AB.PA) has a profitability rating of 1 / 10.

Can you provide the financial health for AB stock?

The financial health rating of AB SCIENCE SA (AB.PA) is 0 / 10.

AB SCIENCE SA (AB.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

AB SCIENCE SA / AB.PA FAQ

What is the fundamental rating for AB stock?

What is the valuation status of AB SCIENCE SA (AB.PA) stock?

How profitable is AB SCIENCE SA (AB.PA) stock?

Can you provide the financial health for AB stock?